Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanyang Nan

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Clinical and Translational Medicine|October 29, 2024
Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapyAn Zhu, Yu Bai, Yanyang Nan, et al.
Biomaterials|April 9, 2026
EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancerXingxing Shang, Ziyi Zhang, Tao Wu, et al.
Biomedicines|September 28, 2024
Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder CancerXiting Huang, Qian Wang, Yanyang Nan, et al.
International Journal of Molecular Sciences|July 29, 2023
Innate Immunity in Cancer Biology and TherapyYuxia Zhang, Wenjing Xue, Caili Xu, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2020
Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacyChang Liu, Yanyang Nan, Zhifeng Xia, et al.
Frontiers in Immunology|December 22, 2022
Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphomaYichen Wang, Xuyao Zhang, Caili Xu, et al.
Nanoscale|May 4, 2018
Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosisXuyao Zhang, Jingyun Luan, Wei Chen, et al.
Biomedicines|May 27, 2026
Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLCKaicheng Zhou, Yanyang Nan, Mengyang Li, et al.
Cell Death Discovery|September 3, 2024
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancerWenjing Xue, Caili Xu, Kaiqi Zhang, et al.
Anti-Cancer Agents in Medicinal Chemistry|June 5, 2020
Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) InhibitorsZhifeng Xia, Yanyang Nan, Chang Liu, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Clinical and Translational Medicine|October 29, 2024
Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapyAn Zhu, Yu Bai, Yanyang Nan, et al.
Biomaterials|April 9, 2026
EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancerXingxing Shang, Ziyi Zhang, Tao Wu, et al.
Biomedicines|September 28, 2024
Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder CancerXiting Huang, Qian Wang, Yanyang Nan, et al.
International Journal of Molecular Sciences|July 29, 2023
Innate Immunity in Cancer Biology and TherapyYuxia Zhang, Wenjing Xue, Caili Xu, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2020
Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacyChang Liu, Yanyang Nan, Zhifeng Xia, et al.
Frontiers in Immunology|December 22, 2022
Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphomaYichen Wang, Xuyao Zhang, Caili Xu, et al.
Nanoscale|May 4, 2018
Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosisXuyao Zhang, Jingyun Luan, Wei Chen, et al.
Biomedicines|May 27, 2026
Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLCKaicheng Zhou, Yanyang Nan, Mengyang Li, et al.
Cell Death Discovery|September 3, 2024
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancerWenjing Xue, Caili Xu, Kaiqi Zhang, et al.
Anti-Cancer Agents in Medicinal Chemistry|June 5, 2020
Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) InhibitorsZhifeng Xia, Yanyang Nan, Chang Liu, et al.
Pageof 3